{"id":"W3087401339","doi":"10.1200/jco.20.02110","title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Population; Oncology; Melanoma; Lymph node; Cancer; Stage (stratigraphy); Surgery; Gastroenterology; Pathology; Immunotherapy; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006567489,0.0002901598,0.002995708,0.0001058387,0.00005982171,0.00001813809,0.0008185719,0.0006904004,0.000685111],"category_scores_gemma":[0.009787506,0.0001763639,0.0009937671,0.0004166983,0.0004811565,0.000127498,0.0001674691,0.002102517,0.00001075444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000175151,"about_ca_system_score_gemma":0.002066949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002632262,"about_ca_topic_score_gemma":0.002712057,"domain_scores_codex":[0.9914553,0.001252668,0.005619682,0.0004424808,0.0008330629,0.0003968582],"domain_scores_gemma":[0.9876714,0.006260532,0.004553722,0.000649948,0.0004772169,0.0003871395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8880237,0.001109184,0.01600188,0.00001380564,0.001241439,0.0004920474,0.0009039342,0.00002104491,0.0002994249,0.00007820051,0.01560968,0.07620562],"study_design_scores_gemma":[0.6066617,0.03102164,0.2884036,0.0002123727,0.000848226,0.00002768648,0.0006634151,0.0002025849,0.0002354801,0.0004331039,0.07104573,0.0002444322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9673995,0.001144064,0.00005589148,0.02374356,0.005606128,0.0006179881,0.0004991509,0.00001451078,0.0009192232],"genre_scores_gemma":[0.9908791,0.003102712,0.0003770405,0.00232737,0.002951954,0.000004953206,0.00007326034,0.00002876141,0.0002548567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.281362,"threshold_uncertainty_score":0.9985535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1106583319210831,"score_gpt":0.3944431596250101,"score_spread":0.2837848277039271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}